PMID- 21488160
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20131121
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 56
IP  - 7
DP  - 2011 Jul 1
TI  - Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine.
PG  - 1133-5
LID - 10.1002/pbc.22865 [doi]
AB  - Aplastic anemia (AA) is an immune-mediated disease. Although most patients are 
      responsive to immunosuppressive therapy (IST) with a combination of 
      anti-thymocyte globulin (ATG) and cyclosporine (CsA), some patients relapse or 
      are refractory to IST. Sirolimus (rapamysin) inhibits the serine-threonine kinase 
      mammalian target of rapamysin (mTOR), and blocks CsA-resistant and 
      calcium-independent pathways late in the progression of the T-cell cycle. We 
      report two cases of AA which relapsed after CsA and ATG plus CsA, respectively. 
      They achieved transfusion independence after retreatment with sirolimus in 
      combination with a CsA.
CI  - Copyright (c) 2011 Wiley-Liss, Inc.
FAU - He, Guangsheng
AU  - He G
AD  - Key Laboratory of Thrombosis and Hematostasis of Ministry of Health, Jiangsu 
      Insititute of Hematology, Department of Hematology of First Affiliated Hospital 
      of Soochow University, Suzhou, Jiangsu Province, P.R. China. 
      heguangsheng@medmail.com.cn
FAU - Zhang, Xiang
AU  - Zhang X
FAU - Wu, Depei
AU  - Wu D
FAU - Sun, Aining
AU  - Sun A
FAU - Wang, Xiuli
AU  - Wang X
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110211
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Anemia, Aplastic/*drug therapy
MH  - Antilymphocyte Serum/*therapeutic use
MH  - Child
MH  - Cyclosporine/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Recurrence
MH  - Sirolimus/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/04/14 06:00
MHDA- 2011/06/15 06:00
CRDT- 2011/04/14 06:00
PHST- 2010/02/22 00:00 [received]
PHST- 2010/09/13 00:00 [accepted]
PHST- 2011/04/14 06:00 [entrez]
PHST- 2011/04/14 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.1002/pbc.22865 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2011 Jul 1;56(7):1133-5. doi: 10.1002/pbc.22865. Epub 2011 
      Feb 11.